Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99 years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). Results Survival from type I epithelial ovarian tumours for women diagnosed during 2005–09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20–45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). Conclusions There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.
|Number of pages||9|
|State||Published - Feb 1 2017|
Bibliographical noteFunding Information:
We would like to thank Mr. John Butler for proposing the idea for the manuscript and Dr. Martin Gore for helpful advice on classification of ovarian tumours. This work was funded by the Canadian Partnership Against Cancer , Cancer Focus Northern Ireland , Cancer Institute New South Wales , Cancer Research UK ( C1336/ A16148 ), US Centers for Disease Control and Prevention (CDC; 12FED03123 , ACO12036 ), Swiss Re, Swiss Cancer Research foundation , Swiss Cancer League , and the University of Kentucky ( 3049024672-12-568 ). Salmerón's work was supported by the Séneca Foundation Programme “Jiménez de la Espada” ( 19652/EE/14 ).
© 2016 Elsevier Inc.
- ovarian cancer
ASJC Scopus subject areas
- Obstetrics and Gynecology